← Back to Search

Monoclonal Antibodies

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Phase 2
Waitlist Available
Research Sponsored by Telavant, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial tests a new medication by first comparing different doses. After that, all participants receive the actual medication for several months, followed by a follow-up period.

Eligible Conditions
  • Ulcerative Colitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

9Treatment groups
Experimental Treatment
Placebo Group
Group I: Cohort 9Experimental Treatment2 Interventions
Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
Group II: Cohort 8Experimental Treatment2 Interventions
Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
Group III: Cohort 7Experimental Treatment2 Interventions
Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
Group IV: Cohort 6Experimental Treatment2 Interventions
Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
Group V: Cohort 5Experimental Treatment2 Interventions
Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
Group VI: Cohort 3Experimental Treatment2 Interventions
Induction - Placebo SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
Group VII: Cohort 2Experimental Treatment2 Interventions
Induction - Placebo SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
Group VIII: Cohort 1Experimental Treatment2 Interventions
Induction - Placebo SC Q4W, (sub-cutaneous every 4 weeks) Chronic- PF-06480605 50 mg SC Q4W
Group IX: Cohort 4Placebo Group2 Interventions
Induction- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Induction- PF-06480605 150 mg SC Q4W
2019
Completed Phase 2
~250
Induction- PF-06480605 450 mg SC Q4W
2019
Completed Phase 2
~250
Chronic- PF-06480605 50 mg SC Q4W
2019
Completed Phase 2
~250
Chronic- PF-06480605 150 mg SC Q4W
2019
Completed Phase 2
~250
Chronic- PF-06480605 450 mg SC Q4W
2019
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Telavant, Inc.Lead Sponsor
5 Previous Clinical Trials
179 Total Patients Enrolled
Hoffmann-La RocheLead Sponsor
2,463 Previous Clinical Trials
1,102,881 Total Patients Enrolled
9 Trials studying Ulcerative Colitis
3,766 Patients Enrolled for Ulcerative Colitis
PfizerIndustry Sponsor
4,675 Previous Clinical Trials
28,716,936 Total Patients Enrolled
33 Trials studying Ulcerative Colitis
425,936 Patients Enrolled for Ulcerative Colitis
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,556 Previous Clinical Trials
25,757,792 Total Patients Enrolled
26 Trials studying Ulcerative Colitis
11,753 Patients Enrolled for Ulcerative Colitis
~41 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top